Cotrimoxazole And Sulphamethaxazole

# Cotrimoxazole (Trimethoprim/Sulfamethoxazole) ## Overview - **Classification**: Antibiotic, Sulfonamide (sulfamethoxazole) and Dihydrofolate Reductase Inhibitor (trimethoprim). - **Mechanism**: Blocks two sequential steps in bacterial folic acid synthesis, leading to synergistic bacteriostatic or bactericidal activity. ## Primary Indications 1. **Urinary Tract Infections (UTIs)** - Treatment of uncomplicated and complicated UTIs. 2. **Pneumocystis Pneumonia (PCP)** - Treatment and prophylaxis in immunocompromised patients (e.g., HIV). 3. **Acute Exacerbations of Chronic Bronchitis (AECB)** - Treatment of susceptible bacterial infections. 4. **Shigellosis and Traveler's Diarrhea** - Treatment of susceptible gastrointestinal infections. 5. **Nocardiosis** - Treatment of Nocardia infections. ## Adult Dosing ### Standard Dosing **Uncomplicated Urinary Tract Infection (UTI)** - **Dose**: **160 mg TMP / 800 mg SMX** (1 Double Strength tablet) - **Frequency**: Every 12 hours - **Route**: Oral - **Duration**: 3 to 7 days **Pneumocystis Pneumonia (PCP) - Treatment** - **Dose**: **15-20 mg/kg TMP / 75-100 mg/kg SMX** (based on TMP) - **Frequency**: Divided every 6-8 hours - **Route**: Oral or IV - **Duration**: 14 to 21 days **Pneumocystis Pneumonia (PCP) - Prophylaxis** - **Dose**: **160 mg TMP / 800 mg SMX** (1 Double Strength tablet) - **Frequency**: Once daily or 3 times weekly - **Route**: Oral ### Dose Adjustments - **Renal Impairment**: - CrCl **15-30 mL/min**: Reduce dose by 50%. - CrCl **<15 mL/min**: Not recommended; if essential, use with extreme caution and monitoring. - **Hepatic Impairment**: No specific dose adjustments, but use with caution due to metabolism. - **Elderly Patients**: Increased risk of adverse effects (renal, hematologic). Monitor closely. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Generally **contraindicated** due to risk of kernicterus (hyperbilirubinemia). - **Special Notes**: Use only in life-threatening situations where no alternatives exist, with extreme caution and monitoring. ### Infants (1-12 months) **Pneumocystis Pneumonia (PCP) - Treatment** - **Dose**: **15-20 mg/kg TMP / 75-100 mg/kg SMX** (based on TMP) - **Frequency**: Divided every 6-8 hours - **Maximum**: **320 mg TMP / 1600 mg SMX** per dose. - **Special Notes**: Oral suspension available (**40 mg TMP / 200 mg SMX** per 5 mL). **Other Infections (e.g., UTI)** - **Dose**: **6-12 mg/kg TMP / 30-60 mg/kg SMX** (based on TMP) - **Frequency**: Divided every 12 hours - **Maximum**: **320 mg TMP / 1600 mg SMX** per dose. ### Children (1-12 years) **Pneumocystis Pneumonia (PCP) - Treatment** - **Dose**: **15-20 mg/kg TMP / 75-100 mg/kg SMX** (based on TMP) - **Frequency**: Divided every 6-8 hours - **Maximum**: Not to exceed **adult dose equivalent**. **Other Infections (e.g., UTI, Otitis Media)** - **Dose**: **6-12 mg/kg TMP / 30-60 mg/kg SMX** (based on TMP) - **Frequency**: Divided every 12 hours - **Maximum**: Not to exceed **adult dose equivalent**. - **Special Notes**: Oral suspension or chewable tablets available. ### Adolescents (13-18 years) - **Dose**: Generally **approach adult dosing** based on weight and severity. - **Maximum**: **Adult maximum dose** for respective indications. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to trimethoprim or sulfonamides. - **Absolute**: Documented megaloblastic anemia due to folate deficiency. - **Absolute**: Severe hepatic impairment or severe renal impairment (CrCl <15 mL/min). - **Absolute**: Infants **<2 months** of age (risk of kernicterus). - **Absolute**: Pregnancy at term and during lactation. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, vomiting, rash (maculopapular). - **Common (1-10%)**: Diarrhea, headache, photosensitivity, hyperkalemia. - **Serious but Rare**: Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), agranulocytosis, aplastic anemia, hepatic necrosis, acute kidney injury. ### Key Drug Interactions - **Warfarin**: Potentiates anticoagulant effect; increased INR, bleeding risk. Monitor INR closely, consider alternative. - **Methotrexate**: Increased methotrexate levels due to decreased renal excretion and displacement; increased toxicity. Avoid or monitor closely for myelosuppression. - **Potassium-sparing diuretics/ACE inhibitors/ARBs**: Increased risk of hyperkalemia. Monitor serum potassium levels. - **Phenytoin**: Increased phenytoin levels due to decreased metabolism; increased toxicity. Monitor phenytoin levels. - **Digoxin**: Increased digoxin levels; monitor digoxin levels. ## Monitoring & Follow-up - **Before Treatment**: Baseline Complete Blood Count (CBC) with differential, renal function (BUN/Cr), Liver Function Tests (LFTs). - **During Treatment**: - **Long-term/high dose**: Weekly CBC, renal function, potassium. - **Short-term**: Monitor for signs of serious adverse reactions (e.g., rash, fever). - **Clinical Signs**: Watch for severe rash, fever, jaundice, unexplained bruising/bleeding, muscle weakness, or signs of hyperkalemia. ## Clinical Pearls - 💡 **Hydration**: Advise patients to maintain adequate hydration to prevent crystalluria and kidney stones. - 💡 **Photosensitivity**: Counsel patients on increased risk of sunburn; advise protective clothing and sunscreen. - 💡 **Folic Acid**: Consider adjunctive folic acid for patients on high doses or prolonged treatment, especially those at risk of folate deficiency. - 💡 **IV Compatibility**: IV formulation requires dilution; do not mix with other drugs or solutions. - 💡 **Allergy**: Always confirm sulfonamide allergy before prescribing; cross-reactivity with non-antibiotic sulfonamides is low but possible. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.